Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

British Journal of Surgery

Volumn 98, Issue 8, 2011, Pages 1041-1055

  Ansari, D ^a   Rosendahl, A ^a   Elebro, J ^b   Andersson, R ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PROGNOSIS; REVIEW;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960006148     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7574     Document Type: Review

References (183)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al., Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004; 198: 722-731. (Pubitemid 38542900)
4. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M,. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27: 324-329. (Pubitemid 36920145)
5. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al., 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210.
6. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al., Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
7. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP,. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9: 99-132. (Pubitemid 351611725)
8. Moher D, Liberati A, Tetzlaff J, Altman DG,; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
9. Gould Rothberg BE, Bracken MB, Rimm DL,. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101: 452-474.
10. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al., Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184. (Pubitemid 41258223)
11. Hidalgo M,. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
12. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
13. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al., Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 2846-2850. (Pubitemid 38509164)
14. Skalicky DA, Kench JG, Segara D, Coleman MJ, Sutherland RL, Henshall SM, et al., Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1941-1947. (Pubitemid 44664272)
15. Linder S, Parrado C, Falkmer UG, BlÃsjö M, Sundelin P, von Rosen A,. Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material. Br J Cancer 1997; 76: 54-59. (Pubitemid 27250076)
16. Shyr YM, Su CH, Li AF, Wu CW, Lui WY,. The role of MIB-1 index in the prognosis of resectable pancreatic head cancer. Hepatogastroenterology 1999; 46: 2968-2973. (Pubitemid 29525316)
17. Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T, et al., Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology 2010; 42: 229-234.
18. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, et al., Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006; 12: 6043-6048. (Pubitemid 44703767)
19. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, et al., HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 2009; 100: 1243-1247.
20. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, et al., Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 2010; 10: 59.
21. Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al., Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2008; 14: 7043-7049.
22. Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, Maemura K, et al., Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 2007; 97: 405-411. (Pubitemid 47196750)
23. Tezel E, Hibi K, Nagasaka T, Nakao A,. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000; 6: 4764-4767. (Pubitemid 32110417)
24. Hirono S, Yamaue H, Hoshikawa Y, Ina S, Tani M, Kawai M, et al., Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling. Cancer Sci 2010; 101: 259-266.
25. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, et al., Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009; 69: 2950-2955.
26. Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA, et al., p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery 2000; 128: 520-530.
27. Lu CD, Morita S, Ishibashi T, Hara H, Isozaki H, Tanigawa N,. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999; 85: 1250-1260. (Pubitemid 29125077)
28. Juuti A, Nordling S, Louhimo J, Lundin J, von Boguslawski K, Haglund C,. Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer. Oncology 2003; 65: 371-377. (Pubitemid 38064950)
29. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, et al., Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 2004; 11: 277-284.
30. Kristiansen G, Jacob J, Buckendahl AC, Grutzmann R, Alldinger I, Sipos B, et al., Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 2006; 12: 6444-6451. (Pubitemid 44799717)
31. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-4121. (Pubitemid 34044636)
32. Wang P, Fan J, Chen Z, Meng ZQ, Luo JM, Lin JH, et al., Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol 2009; 16: 826-835.
33. Hashimoto K, Nio Y, Sumi S, Toga T, Omori H, Itakura M, et al., Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas 2001; 22: 341-347. (Pubitemid 32402082)
34. Nio Y, Omori H, Hashimoto K, Itakura M, Koike M, Yano S, et al., Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res 2005; 25: 3523-3529. (Pubitemid 41105235)
35. Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, et al., Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol 2001; 76: 188-196. (Pubitemid 32240229)
36. Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT,. Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J Gastroenterol 2005; 11: 2744-2747. (Pubitemid 40704240)
37. Sasada T, Azuma K, Hirai T, Hashida H, Kanai M, Yanagawa T, et al., Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer. Ann Surg Oncol 2008; 15: 609-617.
38. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, et al., Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 2004; 136: 443-448. (Pubitemid 39037686)
39. Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, et al., Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer 2005; 92: 2225-2232. (Pubitemid 40966261)
40. Huang J, Yao WY, Zhu Q, Tu SP, Yuan F, Wang HF, et al., XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Sci 2010; 101: 559-567.
41. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al., Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79: 1553-1563. (Pubitemid 29116820)
42. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y,. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001; 92: 1788-1797. (Pubitemid 32952497)
43. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C,. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006; 59: 382-386.
44. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, et al., Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007; 6: 1569-1575. (Pubitemid 351590328)
45. Fong D, Hermann M, Untergasser G, Pirkebner D, Draxl A, Heitz M, et al., Dkk-3 expression in the tumor endothelium: a novel prognostic marker of pancreatic adenocarcinomas. Cancer Sci 2009; 100: 1414-1420.
46. Takagi K, Takada T, Amano H,. A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer. J Gastroenterol 2005; 40: 402-408.
47. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, et al., Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64: 3533-3537. (Pubitemid 38657928)
48. Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, et al., Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005; 11: 2531-2539. (Pubitemid 40569450)
49. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, et al., Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 2007; 30: 1359-1367.
50. Ai KX, Lu LY, Huang XY, Chen W, Zhang HZ,. Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol 2008; 14: 1931-1935. (Pubitemid 351523827)
51. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, et al., Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006; 106: 1677-1684.
52. Welsch T, Keleg S, Bergmann F, Bauer S, Hinz U, Schmidt J,. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma. Pancreas 2009; 38: 968-976.
53. Grützmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, et al., ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004; 90: 1053-1058. (Pubitemid 38495828)
54. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, et al., Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009; 101: 457-464.
55. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, et al., Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 2003; 9: 1503-1508. (Pubitemid 36418408)
56. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, et al., Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87: 1140-1144. (Pubitemid 35418110)
57. Nakata B, Fukunaga S, Noda E, Amano R, Yamada N, Hirakawa K,. Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology 2008; 74: 69-75. (Pubitemid 351915012)
58. Matros E, Bailey G, Clancy T, Zinner M, Ashley S, Whang E, et al., Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer 2006; 106: 693-702. (Pubitemid 43157634)
59. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, et al., Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630.
60. Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, et al., High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009; 100: 1444-1451.
61. Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, et al., Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol 2003; 21: 659-667. (Pubitemid 46621900)
62. Yeh TS, Tseng JH, Liu NJ, Chen TC, Jan YY, Chen MF,. Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg 2005; 140: 1184-1190.
63. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, et al., Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002; 8: 2570-2575. (Pubitemid 34856341)
64. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al., Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010; 17: 2213-2221.
65. Liau SS, Rocha F, Matros E, Redston M, Whang E,. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008; 113: 302-314.
66. Sawai H, Funahashi H, Matsuo Y, Yamamoto M, Okada Y, Hayakawa T, et al., Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci 2003; 48: 1241-1250. (Pubitemid 36793900)
67. Takamura M, Sakamoto M, Ino Y, Shimamura T, Ichida T, Asakura H, et al., Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci 2003; 94: 425-430. (Pubitemid 36790474)
68. Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, et al., Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res 2009; 28: 9.
69. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al., Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19: 1118-1127. (Pubitemid 32176289)
70. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, et al., MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005; 58: 845-852. (Pubitemid 41113392)
71. Takahashi S, Oda T, Hasebe T, Sasaki S, Kinoshita T, Konishi M, et al., Overexpression of sialyl Lewis x antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma. Pathobiology 2001; 69: 127-135. (Pubitemid 34212083)
72. Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, Yamada T, et al., Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15: 2864-2871.
73. Oida Y, Yamazaki H, Tobita K, Mukai M, Ohtani Y, Miyazaki N, et al., Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol Rep 2006; 16: 457-463.
74. Vimalachandran D, Greenhalf W, Thompson C, Luttges J, Prime W, Campbell F, et al., High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005; 65: 3218-3225. (Pubitemid 40524604)
75. Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, et al., CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 2009; 16: 2531-2538.
76. Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo Y, et al., High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 2002; 99: 418-423. (Pubitemid 34495856)
77. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, et al., Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 2010; 28: 1358-1365.
78. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, et al., Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008; 47: 701-706.
79. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al., Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195.
80. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al., Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-2919.
81. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al., CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-1397. (Pubitemid 351543575)
82. Segara D, Biankin AV, Kench JG, Langusch CC, Dawson AC, Skalicky DA, et al., Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005; 11: 3587-3596. (Pubitemid 40627916)
83. Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T, et al., LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia 2009; 11: 12-19.
84. Koizumi M, Doi R, Toyoda E, Masui T, Tulachan SS, Kawaguchi Y, et al., Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003; 134: 260-266. (Pubitemid 37070347)
85. Truan N, Vizoso F, Fresno MF, Fernandez R, Quintela I, Alexandre E, et al., Expression and clinical significance of pepsinogen C in resectable pancreatic cancer. Int J Biol Markers 2001; 16: 31-36. (Pubitemid 32243579)
86. Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K, Manabe T, et al., Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J Cancer Res 1996; 87: 641-649. (Pubitemid 26235556)
87. Yamamoto S, Tomita Y, Hoshida Y, Nagano H, Dono K, Umeshita K, et al., Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2004; 11: 165-172. (Pubitemid 40486791)
88. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D,. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 1648-1652.
89. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, et al., Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003; 9: 4165-4171. (Pubitemid 37204035)
90. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al., High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-1295.
91. Gould Rothberg BE, Rimm DL,. Biomarkers: the useful and the not so useful-an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010; 130: 1971-1987.
92. Gansauge F, Gansauge S, Schmidt E, Müller J, Beger HG,. Prognostic significance of molecular alterations in human pancreatic carcinoma-an immunohistological study. Langenbecks Arch Surg 1998; 383: 152-155. (Pubitemid 28442529)
93. Lebe B, Sadol O, Ulukuş C, Coker A, Karademir S, Astarcioglu H, et al., The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract 2004; 200: 389-396. (Pubitemid 38960635)
94. Loertzer H, Hinze R, Knolle J, Rath FW, Schmassmann A,. Significance of proliferative activity and DNA ploidy in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 1999; 26: 77-83.
95. Luttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G,. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 2000; 191: 154-161. (Pubitemid 30394893)
96. Mäkinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M,. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res 1998; 18: 615-618. (Pubitemid 28174881)
97. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ,. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 886-892. (Pubitemid 34271023)
98. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, et al., Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 2003; 186: 486-492. (Pubitemid 37352833)
99. Welsch T, Kleeff J, Friess H,. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007; 7: 504-521. (Pubitemid 47244895)
100. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al., p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313-323. (Pubitemid 29094081)
101. Culhaci N, Sagol O, Karademir S, Astarcioglu H, Astarcioglu I, Soyturk M, et al., Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer 2005; 5: 98.
102. Feakins RM, Ghaffar AH,. p27 Kip1 expression is reduced in pancreatic carcinoma but has limited prognostic value. Hum Pathol 2003; 34: 385-390. (Pubitemid 36535024)
103. Mielko J, Polkowski WP, Skomra DG, Stanis3awek AJ, Kurylcio AM, Korobowicz EM,. Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region. HPB (Oxford) 2006; 8: 216-222. (Pubitemid 43832452)
104. Joerger AC, Fersht AR,. Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008; 77: 557-582.
105. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al., K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560. (Pubitemid 24106422)
106. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al., p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033. (Pubitemid 24187791)
107. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowskal H, Strzelczyk J, Janiak A, et al., Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepatogastroenterology 2006; 53: 608-612. (Pubitemid 44386969)
108. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, et al., Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 1999; 3: 263-277.
109. Campani D, Boggi U, Cecchetti D, Esposito I, Ceccarelli F, D'Antonio L, et al., p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas 1999; 19: 26-32. (Pubitemid 29293505)
110. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, et al., Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. Am J Clin Pathol 1998; 110: 16-23. (Pubitemid 28294730)
111. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, et al., Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997; 21: 127-143. (Pubitemid 27278611)
112. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, et al., Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101: 684-688. (Pubitemid 24169297)
113. Dong M, Nio Y, Tamura K, Song MM, Guo KJ, Guo RX, et al., Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev 2000; 9: 279-284. (Pubitemid 30165440)
114. Harada N, Gansauge S, Gansauge F, Gause H, Shimoyama S, Imaizumi T, et al., Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer 1997; 76: 299-305. (Pubitemid 27308078)
115. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Motoo Y, et al., Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br J Cancer 1999; 80: 1075-1079. (Pubitemid 29233932)
116. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C,. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996; 53: 104-111. (Pubitemid 26087917)
117. Naka T, Kobayashi M, Ashida K, Toyota N, Kaneko T, Kaibara N,. Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol 1998; 12: 1111-1116.
118. Ohshio G, Suwa H, Imamura T, Yamaki K, Tanaka T, Hashimoto Y, et al., An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas. Scand J Gastroenterol 1998; 33: 535-539. (Pubitemid 28277255)
119. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, et al., Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 1997; 79: 700-716. (Pubitemid 27076336)
120. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, et al., bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 1996; 2: 2015-2022. (Pubitemid 27006634)
121. Virkajärvi N, Pääkkö P, Soini Y,. Association between p53 overexpression, cell proliferation, tumor necrosis and extent of apoptosis in operated pancreatic adenocarcinoma. APMIS 1997; 105: 765-772. (Pubitemid 27450508)
122. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, et al., Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-154. (Pubitemid 24046474)
123. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, et al., DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002; 20: 4531-4542. (Pubitemid 35402956)
124. Gerdes B, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, et al., p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg 2002; 235: 51-59. (Pubitemid 34062399)
125. Hermanova M, Karasek P, Nenutil R, Kyr M, Tomasek J, Baltasova I, et al., Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas 2009; 38: 565-571.
126. Kawesha A, Ghaneh P, Andrén-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al., K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000; 89: 469-474.
127. Magistrelli P, Coppola R, Tonini G, Vincenzi B, Santini D, Borzomati D, et al., Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem 2006; 97: 98-108. (Pubitemid 43050182)
128. Nio Y, Dong M, Uegaki K, Hirahara N, Minari Y, Sasaki S, et al., Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas 1999; 18: 117-126. (Pubitemid 29180107)
129. Sessa F, Bonato M, Bisoni D, Ranzani GN, Capella C,. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival. Eur J Histochem 1998; 42 (Spec No.): 67-76. (Pubitemid 29096896)
130. Sung JY, Kim GY, Lim SJ, Park YK, Kim YW,. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract 2010; 206: 24-29.
131. Massagué J, Blain SW, Lo RS,. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
132. Truty MJ, Urrutia R,. Basics of TGF-beta and pancreatic cancer. Pancreatology 2007; 7: 423-435.
133. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, et al., Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006; 55: 684-698.
134. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al., Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-2475.
135. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al., BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103: 668-675.
136. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, et al., bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998; 43: 414-421. (Pubitemid 28414925)
137. Evans JD, Cornford PA, Dodson A, Greenhalf W, Foster CS, Neoptolemos JP,. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 2001; 1: 254-262. (Pubitemid 33674930)
138. Campani D, Esposito I, Boggi U, Cecchetti D, Menicagli M, De Negri F, et al., Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol 2001; 194: 444-450. (Pubitemid 32782669)
139. Lee MA, Park GS, Lee HJ, Jung JH, Kang JH, Hong YS, et al., Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 2005; 5: 127.
140. Sagol O, Yavuzsen T, Oztop I, Ulukus C, Ylmaz U, Alakavuklar M, et al., The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas 2005; 30: 343-348. (Pubitemid 40586813)
141. Folkman J,. How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes memorial Award lecture. Cancer Res 1986; 46: 467-473. (Pubitemid 16145386)
142. Folkman J,. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6. (Pubitemid 20020880)
143. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM,. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010; 11: 373-382.
144. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K,. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-2245. (Pubitemid 30247122)
145. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB,. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998; 34: 337-340. (Pubitemid 28183830)
146. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, et al., Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998; 34: 1439-1447. (Pubitemid 28370938)
147. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW, et al., Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997; 3: 1309-1316. (Pubitemid 27362391)
148. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al., Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875. (Pubitemid 46849560)
149. Khorana AA, Hu YC, Ryan CK, Komorowski RA, Hostetter G, Ahrendt SA,. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. J Gastrointest Surg 2005; 9: 903-911. (Pubitemid 41224283)
150. Knoll MR, Rudnitzki D, Sturm J, Manegold BC, Post S, Jaeger TM,. Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. Hepatogastroenterology 2001; 48: 1162-1165. (Pubitemid 32757767)
151. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S, Chayama K,. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003; 26: 344-349. (Pubitemid 36529959)
152. Lim YJ, Lee JK, Park CK, Song SY, Jang WY, Ha HY, et al., Prognostic value of VEGF in human pancreatic ductal adenocarcinoma. Korean J Intern Med 2004; 19: 10-14. (Pubitemid 41237482)
153. Matsumoto G, Muta M, Tsuruta K, Horiguchi S, Karasawa K, Okamoto A,. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer. Pancreatology 2007; 7: 167-173. (Pubitemid 47094086)
154. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S,. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000; 28: 31-39.
155. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, et al., High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122-129. (Pubitemid 34815907)
156. Tang RF, Wang SX, Peng L, Zhang M, Li ZF, Zhang ZM, et al., Expression of vascular endothelial growth factors A and C in human pancreatic cancer. World J Gastroenterol 2006; 12: 280-286. (Pubitemid 43336928)
157. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, et al., Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 2007; 67: 7068-7071. (Pubitemid 47206534)
158. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA,. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59: 4356-4362. (Pubitemid 29418754)
159. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD,. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 2002; 6: 838-843.
160. Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, et al., Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2006; 57: 185-190. (Pubitemid 41779837)
161. Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, et al., Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133-138. (Pubitemid 38812432)
162. Bergmann F, Moldenhauer G, Herpel E, Gaida MM, Strobel O, Werner J, et al., Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets? Histopathology 2010; 56: 440-448.
163. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, et al., Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 2002; 17: 914-921.
164. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, et al., Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999; 26: 69-76.
165. Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, et al., Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001; 24: 447-452. (Pubitemid 32959100)
166. Li ZH, Bresnick AR,. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res 2006; 66: 5173-5180. (Pubitemid 43844940)
167. Parker C, Whittaker PA, Usmani BA, Lakshmi MS, Sherbet GV,. Induction of 18A2/mts1 gene expression and its effects on metastasis and cell cycle control. DNA Cell Biol 1994; 13: 1021-1028.
168. Mahon PC, Baril P, Bhakta V, Chelala C, Caulee K, Harada T, et al., S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007; 67: 6786-6795. (Pubitemid 47105526)
169. Ambartsumian N, Klingelhöfer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, et al., The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 2001; 20: 4685-4695. (Pubitemid 32762440)
170. Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H,. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol 2003; 21: 106-112.
171. Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Watanabe Y, et al., Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000; 16: 1125-1131.
172. Ninomiya I, Ohta T, Fushida S, Endo Y, Hashimoto T, Yagi M, et al., Increased expression of S100A4 and its prognostic significance in esophageal squamous cell carcinoma. Int J Oncol 2001; 18: 715-720.
173. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, Cameron JL, et al., Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002; 160: 45-50. (Pubitemid 34052264)
174. Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L, et al., Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000; 60: 1595-1603. (Pubitemid 30183430)
175. Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, Matsuura A, et al., Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 1997; 3: 2309-2316. (Pubitemid 28133150)
176. Yonemura Y, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K, et al., Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000; 6: 4234-4242.
177. Tabata T, Tsukamoto N, Fooladi AA, Yamanaka S, Furukawa T, Ishida M, et al., RNA interference targeting against S100A4 suppresses cell growth and motility and induces apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 2009; 390: 475-480.
178. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al., The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956-6961. (Pubitemid 39383046)
179. Lazebnik Y,. What are the hallmarks of cancer? Nat Rev Cancer 2010; 10: 232-233.
180. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP,. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213-2236. (Pubitemid 41415597)
181. Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D,. Molecular prognostic factors in patients with pancreatic cancer. Expert Opin Ther Targets 2007; 11: 1553-1569. (Pubitemid 350285005)
182. Yeh JJ,. Prognostic signature for pancreatic cancer: are we close? Future Oncol 2009; 5: 313-321.
183. Coate LE, John T, Tsao MS, Shepherd FA,. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10: 1001-1010.